XOMA Completes $10 Million Debt Financing

December 30, 2011

Cahill represented XOMA Corporation, a leader in the discovery and development of antibody therapeutics, and its subsidiaries in connection with a $10.0 million 42-month secured term loan agreement with GE Capital Corporation. The funds will be used for advancement of gevokizumab (XOMA 052), XOMA's lead clinical product candidate, and for general corporate purposes.